Skip to main content
SpringerLink
Log in

A comparison of the carrageenan edema test and ultraviolet light-induced erythema test as predictors of the clinical dose in rheumatoid arthritis

  • Immunosuppression and Inflammation
  • Research Reports
  • Published:
Agents and Actions Aims and scope Submit manuscript

Abstract

Twelve non-steroidal anti-inflammatory agents (NSAI's) and one steroidal anti-inflammatory agent, dexamethasone, were examined in the carrageenan edema test (CET) in the rat and in the ultraviolet light-induced erythema test (UVE) in the guinea pig to evaluate the correlation between those models of inflammation and the clinical dose of the NSAI's in the treatment of rheumatoid arthritis. The regression of the logarithm of the clinical dose with the logarithm of the ED50 for UVE gave a slope of 0.54 implying a non-parallelism of assays and a difference in mechanism. Dexamethasone failed to inhibit the UVE thereby corroborating this point. The parallelism of the logarithm of the clinical dose with the logarithm of the ED50 for the CET was substantially better (slope=0.86). Dexamethasone was active in CET and its dose would be predicted by the CET regression. When only one variable was used for a prediction, log(CET) was a better predictor of log (clinical dose) than log(UVE). Standard methods for best regression selection indicated that even when both predictor variables were considered, log(CET) alone gave the best regression equation for predicting clinical dose. The view that inhibition of prostaglandin biosynthesis is the primary anti-inflammatory mechanism of NSAI's in rheumatoid arthritis is discussed in terms of these findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. G. Wilhemi,Über die pharmakologischen Eigen schaften von Irgapyrin, einem neuen Praparat aus der Pyrazolreihe, Schweiz. Med. Wchnschr.79, 577–582 (1949).

    Google Scholar 

  2. G. Wilhemi,Ueber die antiphlogistische Wirkung von Pyrazolen, speziell Irgapyrin, bei peroraler und parenteraler Verabreichung, Schweiz. Med. Wchnschr.80, 936–940 (1950).

    Google Scholar 

  3. C.V. Winder, J. Wax, V. Burr, M. Been andC.E. Rosiere,A Study of Pharmacological Influences on Ultraviolet Erythema in Guinea Pigs, Arch. Int. Pharmacodyn.116, 261–292 (1958).

    PubMed  Google Scholar 

  4. C.A. Winter, E.A. Risley andG.W. Nuss,Carrageenan-Induced Edema in Hind Paw of the Rat as an Assay for Antiinflammatory Drugs, Proc. Soc. Exp. Biol. Med.111, 544–547 (1962).

    PubMed  Google Scholar 

  5. N. Gupta andL. Levy,Delayed Manifestation of Ultraviolet Reaction in the Guinea Pig Caused by Anti-Inflammatory Drugs, Br. J. Pharmac.47, 240–248 (1973).

    Google Scholar 

  6. E.M. Bavin, T.J. Drain, D.E. Seymour andP.D. Waterhouse,Antiinflammatory Compounds, The Activity of a Series of New Compounds Compared with Phenylbutazone and Cortisone, J. Pharm. 7, 1022–1031 (1955).

    Google Scholar 

  7. J.R. Vane,Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drug, Nature231, 232–233 (1971).

    PubMed  Google Scholar 

  8. D.S. Synder,Effect of Topical Indomethacin on UVR-induced Redness and Prostaglandin E Levels in Sunburn Guinea Pig Skin Prostaglandins11, 631–643 (1976).

    PubMed  Google Scholar 

  9. A.L. Willis,Parallel Assay of Prostaglandin-like Activity in Rat Inflammatory Exudate by Means of Cascade Superfusion, J. Pharm. Pharmacol.21, 126–128 (1969).

    PubMed  Google Scholar 

  10. J.G. Lombardino, I.G. Otterness andE.H. Wiseman,Acidic Antiinflammatory Agents—Correlations of Some Physical, Pharmacological and Clinical Data, Arzneim.-Forsch.25, 1629–1635 (1975).

    Google Scholar 

  11. E.H. Wiseman, Y.-H. Chang andJ.G. Lombardino,Piroxicam, a Novel Anti-inflammatory Agent, Arzneim.-Forsch.26, 1300–1303 (1976).

    Google Scholar 

  12. K.F. Swingle, R.R. Hamilton, J.K. Harrington andK.C. Kvam,3-Benzoyldifluoromethane-sulfonanilide, Sodium Salt (Diflumidone Sodium, MBR 4164-8): A New Antiinflammatory Agent, Arch. Int. Pharmacodyn.189, 129–144 (1971).

    PubMed  Google Scholar 

  13. S.S. Adams, D.F. McCullough andJ.S. Nicholson,The Pharmacological Properties of Ibuprofen, an Anti-inflammatory, Analgesic and Antipyretic Agent, Arch. Int. Pharmacodyn.178, 115–129 (1969).

    PubMed  Google Scholar 

  14. L. Julou, J.C. Guyonnet, R. Ducrot, J. Fournel andJ. Pasquet,Ketoprofen (19.583 R.P.), Main Pharmacological Properties—Outline of Toxicological and Pharmacokinetic Data, Scand. J. Rheum. Suppl.14, 33–44 (1976).

    Google Scholar 

  15. S. Wong, J.F. Gardocki andT.P. Pruss Pharmacologic Evaluation of Tolectin (Tolmetin, McN-2559) and McN-2891, Two Anti-Inflammatory Agents, J. Pharm. Exp. Ther.185, 127–138 (1973).

    Google Scholar 

  16. C.V. Winder, J. Wax, B. Serrano, E.M. Jones andM.L. McPhee,Antiinflammatory and Antipyretic Properties of N-(α,α,α-Trifluoro-m-tolyl)anthranilic Acid (CI-440; Flufenamic Acid), Arth. Rheum.6, 36–47 (1963).

    Google Scholar 

  17. S.S. Adams, K.F. McCullough andJ.S. Nicholson,Some Biological Properties of Flurbiprofen, an Anti-inflammatory, Analgesic and Antipyretic Agent, Arzneim.-Forsch.25, 1786–1791 (1975).

    Google Scholar 

  18. N.R. Draper andH. Smith,Applied Regression Analysis (John Wiley & Sons, New York, 1966).

    Google Scholar 

  19. J. Sondergaard andM.W. Greaves,Pharmacologic Studies in Inflammation Due to Exposure to Ultraviolet Radiation, J. Pathol.101, 93–97 (1970).

    PubMed  Google Scholar 

  20. G.P. Mathur andV.M. Ghandi,Prostaglandin in Human and Albino Skin, J. Invest. Dermatol.58, 291–295 (1972).

    PubMed  Google Scholar 

  21. R. Flower, R. Gryglewski, K. Herbaczynska-Cedro andJ.R. Vane,Effect of Antiinflammatory Drugs on Prostaglandin Biosynthesis, Nature New Biol.238, 104–105 (1972).

    PubMed  Google Scholar 

  22. A. Danon andG. Assouline,Inhibition of Prostaglanding Biosynthesis by Corticosteroids Requires RNA and Protein Synthesis, Nature273, 552–554 (1978).

    PubMed  Google Scholar 

  23. M. Dirosa, J.P. Giroud andD.A. Willoughby,Studies of the Mediators of the Acute Inflammatory Response Induced in Rats in Different Sites by Carrageenan and Turpentine, J. Pathol.104, 15–29 (1971).

    PubMed  Google Scholar 

  24. J.R. Walker, M.J.H. Smith andA.W. FordHutchinson,Anti-inflammatory Drugs, Prostaglandins and Leucocyte Migration, Agents and Actions615, 602–606 (1976)

    Google Scholar 

  25. I.L. Bonta, H. Bult, J.E. Vincent andF.J. Zijlstra,Acute Antiinflammatory Effect of Aspirin and Dexamethasone in Rats Deprived of Endogenous Prostaglandin Precursors, J. Pharm. Pharmacol.29, 1–7 (1977).

    PubMed  Google Scholar 

  26. S. Moncada, S.H. Ferreira andJ.R. Vane,Prostaglandins, Aspirin-like Drugs and the Oedema of Inflammation, Nature246, 127–128 (1973).

    Google Scholar 

  27. E.C. Huskinsson,Antiinflammatory Drugs, Seminars Arth. Rheum.7, 1–20 (1977).

    Google Scholar 

  28. N.E. Pitts andR.R. Proctor,Summary: Efficacy and Safety of Piroxicam, Royal Soc. Med. Intl. Cong. Symp. Ser.1, 97–108 (1978).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Central Research Division, Pfizer Inc., 06340, Groton, CT, USA

    Ivan G. Otterness, Edward H. Wiseman & Daniel J. Gans

Authors
  1. Ivan G. Otterness
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward H. Wiseman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel J. Gans
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Otterness, I.G., Wiseman, E.H. & Gans, D.J. A comparison of the carrageenan edema test and ultraviolet light-induced erythema test as predictors of the clinical dose in rheumatoid arthritis. Agents and Actions 9, 177–183 (1979). https://doi.org/10.1007/BF02024731

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02024731

Keywords

Search

Navigation